Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myasthenia Gravis | 24 | 2023 | 36 | 5.380 |
Why?
|
T-Lymphocytes, Regulatory | 7 | 2014 | 35 | 2.320 |
Why?
|
Myasthenia Gravis, Autoimmune, Experimental | 7 | 2014 | 7 | 2.090 |
Why?
|
Receptors, Cholinergic | 12 | 2014 | 24 | 1.980 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2012 | 18 | 1.540 |
Why?
|
Autoantibodies | 8 | 2018 | 80 | 1.290 |
Why?
|
Muscle, Skeletal | 9 | 2014 | 397 | 1.180 |
Why?
|
Immunotherapy | 4 | 2017 | 56 | 1.130 |
Why?
|
Mycophenolic Acid | 5 | 2006 | 14 | 1.090 |
Why?
|
Muscle Weakness | 5 | 2014 | 34 | 0.840 |
Why?
|
Immunosuppressive Agents | 7 | 2009 | 140 | 0.750 |
Why?
|
Amyotrophic Lateral Sclerosis | 2 | 2016 | 23 | 0.700 |
Why?
|
Muscular Diseases | 2 | 2018 | 18 | 0.650 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 48 | 0.620 |
Why?
|
Humans | 56 | 2023 | 28436 | 0.620 |
Why?
|
Electrodiagnosis | 3 | 2005 | 5 | 0.590 |
Why?
|
Muscular Atrophy, Spinal | 4 | 2003 | 5 | 0.590 |
Why?
|
Neuromuscular Junction Diseases | 3 | 2015 | 3 | 0.590 |
Why?
|
Muscle Fibers, Skeletal | 3 | 2015 | 46 | 0.580 |
Why?
|
Forkhead Transcription Factors | 4 | 2012 | 23 | 0.570 |
Why?
|
B-Lymphocytes | 2 | 2016 | 56 | 0.560 |
Why?
|
Electromyography | 6 | 2005 | 71 | 0.550 |
Why?
|
Cell Proliferation | 4 | 2014 | 178 | 0.540 |
Why?
|
Treatment Outcome | 9 | 2023 | 3615 | 0.520 |
Why?
|
TDP-43 Proteinopathies | 1 | 2016 | 110 | 0.460 |
Why?
|
Receptors, Nicotinic | 2 | 2012 | 5 | 0.460 |
Why?
|
Antibody Specificity | 2 | 2011 | 35 | 0.460 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2014 | 6 | 0.450 |
Why?
|
Immunoglobulins, Intravenous | 3 | 2014 | 19 | 0.440 |
Why?
|
Muscular Atrophy | 2 | 2018 | 9 | 0.430 |
Why?
|
Female | 29 | 2021 | 15730 | 0.420 |
Why?
|
Mice | 9 | 2014 | 1461 | 0.420 |
Why?
|
Animals | 11 | 2014 | 3780 | 0.410 |
Why?
|
Mice, Inbred C57BL | 6 | 2014 | 435 | 0.400 |
Why?
|
Autoimmunity | 2 | 2010 | 12 | 0.380 |
Why?
|
Male | 29 | 2021 | 15291 | 0.380 |
Why?
|
Adult | 22 | 2018 | 8107 | 0.320 |
Why?
|
Death Domain Receptor Signaling Adaptor Proteins | 1 | 2008 | 1 | 0.310 |
Why?
|
Dendritic Cells | 4 | 2011 | 32 | 0.310 |
Why?
|
Caspase 8 | 1 | 2008 | 9 | 0.310 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2008 | 7 | 0.310 |
Why?
|
Neuroblastoma | 1 | 2008 | 19 | 0.310 |
Why?
|
Middle Aged | 21 | 2018 | 9269 | 0.300 |
Why?
|
Gene Expression Regulation | 1 | 2009 | 281 | 0.290 |
Why?
|
Apoptosis | 1 | 2008 | 205 | 0.280 |
Why?
|
Immune Tolerance | 3 | 2012 | 15 | 0.270 |
Why?
|
Neck Muscles | 1 | 2006 | 5 | 0.270 |
Why?
|
Head Movements | 1 | 2006 | 5 | 0.270 |
Why?
|
Antibodies | 4 | 2009 | 49 | 0.270 |
Why?
|
Hodgkin Disease | 1 | 2006 | 17 | 0.270 |
Why?
|
Radiotherapy | 1 | 2006 | 34 | 0.270 |
Why?
|
Dermatomyositis | 1 | 2006 | 12 | 0.260 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 111 | 0.260 |
Why?
|
Immunoassay | 1 | 2005 | 40 | 0.250 |
Why?
|
Immunoglobulin G | 4 | 2014 | 95 | 0.240 |
Why?
|
Aged | 12 | 2018 | 9277 | 0.220 |
Why?
|
Nervous System Diseases | 1 | 2005 | 121 | 0.220 |
Why?
|
Neural Conduction | 3 | 2001 | 11 | 0.220 |
Why?
|
Interleukin-10 | 2 | 2014 | 20 | 0.210 |
Why?
|
Muscle Fatigue | 1 | 2003 | 12 | 0.210 |
Why?
|
Lymphocyte Activation | 2 | 2014 | 86 | 0.210 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 13 | 0.210 |
Why?
|
CD4 Antigens | 2 | 2012 | 29 | 0.200 |
Why?
|
Polyradiculoneuropathy | 1 | 2002 | 2 | 0.200 |
Why?
|
Polymyositis | 1 | 2002 | 8 | 0.200 |
Why?
|
Immunity, Humoral | 2 | 2014 | 6 | 0.200 |
Why?
|
Gastrostomy | 1 | 2001 | 10 | 0.190 |
Why?
|
Positive-Pressure Respiration | 1 | 2001 | 11 | 0.190 |
Why?
|
Spinal Muscular Atrophies of Childhood | 1 | 2021 | 3 | 0.190 |
Why?
|
Cholinesterase Inhibitors | 3 | 2009 | 15 | 0.190 |
Why?
|
Recombinant Fusion Proteins | 1 | 2021 | 31 | 0.190 |
Why?
|
Muscular Dystrophy, Emery-Dreifuss | 2 | 2011 | 2 | 0.190 |
Why?
|
Double-Blind Method | 4 | 2023 | 433 | 0.190 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2018 | 59 | 0.180 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 97 | 0.180 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2012 | 6 | 0.180 |
Why?
|
Neuromuscular Diseases | 1 | 2000 | 5 | 0.180 |
Why?
|
Axons | 1 | 2000 | 28 | 0.170 |
Why?
|
Biological Products | 1 | 2021 | 45 | 0.170 |
Why?
|
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2000 | 1 | 0.170 |
Why?
|
Torpedo | 2 | 2010 | 2 | 0.170 |
Why?
|
Interferon-alpha | 1 | 2000 | 32 | 0.170 |
Why?
|
X Chromosome | 1 | 1999 | 9 | 0.170 |
Why?
|
Genetic Linkage | 1 | 1999 | 58 | 0.170 |
Why?
|
Membrane Proteins | 3 | 2011 | 171 | 0.170 |
Why?
|
Activities of Daily Living | 1 | 2023 | 608 | 0.160 |
Why?
|
Demyelinating Diseases | 1 | 1999 | 15 | 0.160 |
Why?
|
Motor Neurons | 1 | 1999 | 18 | 0.160 |
Why?
|
Muscular Dystrophies, Limb-Girdle | 1 | 2018 | 1 | 0.160 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 2 | 0.160 |
Why?
|
Bulbo-Spinal Atrophy, X-Linked | 1 | 2018 | 1 | 0.160 |
Why?
|
Neuromuscular Junction | 3 | 2009 | 8 | 0.150 |
Why?
|
Nerve Block | 1 | 1999 | 67 | 0.150 |
Why?
|
Connective Tissue Diseases | 1 | 1997 | 8 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1997 | 29 | 0.140 |
Why?
|
Case-Control Studies | 2 | 2012 | 594 | 0.140 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2017 | 17 | 0.130 |
Why?
|
Reproduction | 1 | 2016 | 10 | 0.130 |
Why?
|
Age of Onset | 3 | 2009 | 99 | 0.130 |
Why?
|
Complement Inactivating Agents | 1 | 2016 | 3 | 0.130 |
Why?
|
Orphan Drug Production | 1 | 2015 | 1 | 0.130 |
Why?
|
Plasma Cells | 1 | 2016 | 6 | 0.130 |
Why?
|
4-Aminopyridine | 1 | 2015 | 5 | 0.130 |
Why?
|
Potassium Channel Blockers | 1 | 2015 | 5 | 0.130 |
Why?
|
Prednisone | 3 | 2006 | 65 | 0.130 |
Why?
|
Thymectomy | 2 | 2009 | 2 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2009 | 988 | 0.130 |
Why?
|
T-Lymphocytes | 1 | 2016 | 97 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2005 | 27 | 0.120 |
Why?
|
Child | 4 | 2021 | 1420 | 0.120 |
Why?
|
Renal Dialysis | 3 | 2004 | 123 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 2 | 2009 | 117 | 0.120 |
Why?
|
DNA Mutational Analysis | 2 | 2011 | 59 | 0.110 |
Why?
|
Physicians | 1 | 2015 | 124 | 0.110 |
Why?
|
Chronic Disease | 3 | 2008 | 441 | 0.110 |
Why?
|
Neurologic Examination | 2 | 2004 | 114 | 0.110 |
Why?
|
Recombinant Proteins | 1 | 2014 | 213 | 0.110 |
Why?
|
Drug Therapy, Combination | 2 | 2006 | 183 | 0.110 |
Why?
|
Cytokines | 2 | 2012 | 230 | 0.100 |
Why?
|
Self Tolerance | 1 | 2012 | 1 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2005 | 517 | 0.100 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2012 | 3 | 0.100 |
Why?
|
Antigen-Presenting Cells | 1 | 2012 | 8 | 0.100 |
Why?
|
Cell Separation | 1 | 2012 | 29 | 0.100 |
Why?
|
Mutation | 2 | 2011 | 353 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2012 | 41 | 0.100 |
Why?
|
In Vitro Techniques | 1 | 2012 | 176 | 0.100 |
Why?
|
Cells, Cultured | 1 | 2014 | 539 | 0.100 |
Why?
|
Autoantigens | 1 | 2012 | 25 | 0.100 |
Why?
|
Cholinergic Antagonists | 1 | 2011 | 11 | 0.100 |
Why?
|
Adoptive Transfer | 1 | 2011 | 32 | 0.090 |
Why?
|
Stem Cells | 1 | 2011 | 41 | 0.090 |
Why?
|
Exons | 1 | 2011 | 33 | 0.090 |
Why?
|
Lamin Type A | 1 | 2011 | 2 | 0.090 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 239 | 0.090 |
Why?
|
Nuclear Proteins | 1 | 2011 | 87 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 2 | 2002 | 80 | 0.090 |
Why?
|
Adsorption | 1 | 2010 | 7 | 0.090 |
Why?
|
Research Design | 1 | 2012 | 207 | 0.090 |
Why?
|
Tissue Scaffolds | 1 | 2010 | 27 | 0.090 |
Why?
|
Myocarditis | 1 | 2010 | 12 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2008 | 192 | 0.090 |
Why?
|
Orthomyxoviridae Infections | 1 | 2010 | 10 | 0.080 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2010 | 12 | 0.080 |
Why?
|
Influenza Vaccines | 1 | 2010 | 11 | 0.080 |
Why?
|
Nanoparticles | 1 | 2010 | 11 | 0.080 |
Why?
|
Bungarotoxins | 1 | 2009 | 1 | 0.080 |
Why?
|
Freund's Adjuvant | 1 | 2009 | 1 | 0.080 |
Why?
|
Action Potentials | 2 | 2000 | 89 | 0.080 |
Why?
|
Neuroimmunomodulation | 1 | 2009 | 9 | 0.080 |
Why?
|
Protein Binding | 1 | 2009 | 132 | 0.080 |
Why?
|
Young Adult | 2 | 2012 | 2069 | 0.080 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 166 | 0.080 |
Why?
|
Alstrom Syndrome | 1 | 2008 | 1 | 0.080 |
Why?
|
Caspase Inhibitors | 1 | 2008 | 5 | 0.080 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2008 | 4 | 0.080 |
Why?
|
Alternative Splicing | 1 | 2008 | 18 | 0.080 |
Why?
|
Protein Isoforms | 1 | 2008 | 48 | 0.080 |
Why?
|
Disease Progression | 2 | 2009 | 717 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 79 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2009 | 308 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2008 | 120 | 0.080 |
Why?
|
Cell Division | 1 | 2008 | 83 | 0.080 |
Why?
|
Adolescent | 3 | 2018 | 2307 | 0.080 |
Why?
|
Pilot Projects | 3 | 2005 | 440 | 0.080 |
Why?
|
Down-Regulation | 1 | 2008 | 102 | 0.070 |
Why?
|
Radioimmunoassay | 2 | 2005 | 17 | 0.070 |
Why?
|
Cell Line, Tumor | 1 | 2008 | 249 | 0.070 |
Why?
|
Sex Factors | 1 | 2009 | 476 | 0.070 |
Why?
|
Factor VII | 2 | 1997 | 2 | 0.070 |
Why?
|
Factor X | 2 | 1997 | 2 | 0.070 |
Why?
|
Protein C | 2 | 1997 | 10 | 0.070 |
Why?
|
Lipoprotein(a) | 2 | 1997 | 5 | 0.070 |
Why?
|
Blood Coagulation | 2 | 1997 | 20 | 0.070 |
Why?
|
Immunization | 1 | 2006 | 17 | 0.070 |
Why?
|
Brachial Plexus Neuropathies | 1 | 2006 | 5 | 0.070 |
Why?
|
Connective Tissue | 1 | 2006 | 23 | 0.070 |
Why?
|
Time | 1 | 2006 | 15 | 0.070 |
Why?
|
Brachial Plexus | 1 | 2006 | 6 | 0.070 |
Why?
|
Spinal Nerve Roots | 1 | 2006 | 15 | 0.070 |
Why?
|
Cohort Studies | 3 | 2018 | 1926 | 0.070 |
Why?
|
Cell Communication | 1 | 2006 | 25 | 0.070 |
Why?
|
Radiation Dosage | 1 | 2006 | 39 | 0.070 |
Why?
|
Age Factors | 1 | 2009 | 781 | 0.070 |
Why?
|
Disease Models, Animal | 1 | 2009 | 619 | 0.070 |
Why?
|
Bronchopneumonia | 1 | 2006 | 1 | 0.070 |
Why?
|
Opportunistic Infections | 1 | 2006 | 8 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2006 | 70 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2006 | 8 | 0.060 |
Why?
|
Complement C1q | 1 | 2006 | 7 | 0.060 |
Why?
|
Plasma Exchange | 2 | 2010 | 12 | 0.060 |
Why?
|
Antigens | 1 | 2005 | 9 | 0.060 |
Why?
|
Botulism | 1 | 2005 | 1 | 0.060 |
Why?
|
Edrophonium | 1 | 2005 | 1 | 0.060 |
Why?
|
Lambert-Eaton Myasthenic Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
Immunologic Tests | 1 | 2005 | 3 | 0.060 |
Why?
|
Biopsy | 3 | 2001 | 220 | 0.060 |
Why?
|
Inflammation | 2 | 2004 | 284 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2005 | 79 | 0.060 |
Why?
|
Child, Preschool | 2 | 2021 | 688 | 0.060 |
Why?
|
Carnitine | 1 | 2004 | 8 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2005 | 82 | 0.060 |
Why?
|
Electric Stimulation | 1 | 2004 | 53 | 0.060 |
Why?
|
Muscle Contraction | 1 | 2004 | 68 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2003 | 128 | 0.050 |
Why?
|
Retrospective Studies | 2 | 2003 | 3612 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 199 | 0.050 |
Why?
|
Motor Neuron Disease | 1 | 2002 | 4 | 0.050 |
Why?
|
Guillain-Barre Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
|
Intubation, Gastrointestinal | 1 | 2001 | 12 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2002 | 70 | 0.050 |
Why?
|
Uremia | 2 | 1998 | 4 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2003 | 737 | 0.050 |
Why?
|
Prednisolone | 1 | 2000 | 8 | 0.040 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2000 | 21 | 0.040 |
Why?
|
Tibial Nerve | 1 | 2000 | 4 | 0.040 |
Why?
|
Genetic Therapy | 1 | 2021 | 85 | 0.040 |
Why?
|
Cyclosporine | 1 | 2000 | 13 | 0.040 |
Why?
|
Facial Muscles | 1 | 1999 | 2 | 0.040 |
Why?
|
Tongue | 1 | 1999 | 10 | 0.040 |
Why?
|
Pedigree | 1 | 1999 | 67 | 0.040 |
Why?
|
Muscular Dystrophies | 1 | 1999 | 2 | 0.040 |
Why?
|
Hypertrophy | 1 | 1999 | 25 | 0.040 |
Why?
|
Electrophysiology | 1 | 1999 | 103 | 0.040 |
Why?
|
Hand Strength | 1 | 2000 | 60 | 0.040 |
Why?
|
Hepatitis C, Chronic | 1 | 2000 | 42 | 0.040 |
Why?
|
Arm | 1 | 1999 | 84 | 0.040 |
Why?
|
Biomarkers | 3 | 2012 | 596 | 0.040 |
Why?
|
Hemodiafiltration | 1 | 1998 | 2 | 0.040 |
Why?
|
Biomimetics | 1 | 2018 | 6 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 1998 | 5 | 0.040 |
Why?
|
Epoprostenol | 1 | 1998 | 7 | 0.040 |
Why?
|
International Cooperation | 1 | 2018 | 24 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 1998 | 49 | 0.040 |
Why?
|
Diet, Protein-Restricted | 1 | 1998 | 4 | 0.040 |
Why?
|
Dietary Proteins | 1 | 1998 | 25 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2000 | 289 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 351 | 0.040 |
Why?
|
Anticoagulants | 1 | 1998 | 90 | 0.040 |
Why?
|
Vasculitis | 1 | 1997 | 29 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2021 | 1859 | 0.030 |
Why?
|
Injections, Subcutaneous | 2 | 2005 | 25 | 0.030 |
Why?
|
Etanercept | 2 | 2005 | 21 | 0.030 |
Why?
|
United States | 2 | 2012 | 2201 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 244 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 1143 | 0.030 |
Why?
|
Advisory Committees | 1 | 2012 | 25 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2006 | 492 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2011 | 2 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2011 | 4 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2011 | 3 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2017 | 553 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2011 | 26 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2011 | 15 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2011 | 21 | 0.020 |
Why?
|
Societies, Medical | 1 | 2012 | 154 | 0.020 |
Why?
|
Canada | 1 | 2011 | 51 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 160 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 199 | 0.020 |
Why?
|
Models, Molecular | 1 | 2011 | 84 | 0.020 |
Why?
|
Hashimoto Disease | 1 | 2010 | 4 | 0.020 |
Why?
|
Encephalitis | 1 | 2010 | 11 | 0.020 |
Why?
|
Cell Line | 1 | 2011 | 280 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2010 | 57 | 0.020 |
Why?
|
Steroids | 1 | 2010 | 26 | 0.020 |
Why?
|
Phospholipids | 1 | 2010 | 10 | 0.020 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 16 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2010 | 53 | 0.020 |
Why?
|
Brain Diseases | 1 | 2010 | 67 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2010 | 362 | 0.020 |
Why?
|
Autopsy | 1 | 2010 | 343 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2011 | 654 | 0.020 |
Why?
|
Complement C1 | 1 | 2006 | 1 | 0.020 |
Why?
|
Complement Membrane Attack Complex | 1 | 2006 | 2 | 0.020 |
Why?
|
Complement C3 | 1 | 2006 | 6 | 0.020 |
Why?
|
Kidney Failure, Chronic | 2 | 1998 | 165 | 0.020 |
Why?
|
Prognosis | 1 | 2005 | 825 | 0.010 |
Why?
|
Leg | 1 | 2001 | 52 | 0.010 |
Why?
|
Time Factors | 1 | 2004 | 1491 | 0.010 |
Why?
|
Prospective Studies | 1 | 2005 | 1809 | 0.010 |
Why?
|
Fibrosis | 1 | 1999 | 30 | 0.010 |
Why?
|
Blood Urea Nitrogen | 1 | 1998 | 1 | 0.010 |
Why?
|
Nephelometry and Turbidimetry | 1 | 1998 | 2 | 0.010 |
Why?
|
Prealbumin | 1 | 1998 | 4 | 0.010 |
Why?
|
Creatinine | 1 | 1998 | 53 | 0.010 |
Why?
|
Nutritional Status | 1 | 1998 | 61 | 0.010 |
Why?
|
Blood Proteins | 1 | 1997 | 19 | 0.010 |
Why?
|